Publications dans lesquelles il/elle collabore avec Guillermo Izquierdo Ayuso (74)

2024

  1. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom

    Journal of medical economics, Vol. 27, Núm. 1, pp. 109-125

  2. Early beginning of alemtuzumab: changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study

    Neurologia, Vol. 39, Núm. 5, pp. 383-391

  3. Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study

    PLOS Digital Health, Vol. 3, Núm. 7

2023

  1. Comparative effectiveness in multiple sclerosis: A methodological comparison

    Multiple Sclerosis Journal, Vol. 29, Núm. 3, pp. 326-332

  2. Disability accrual in primary and secondary progressive multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 94, Núm. 9, pp. 707-717

  3. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

    Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644

2022

  1. Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study

    Neurology, Vol. 98, Núm. 24, pp. E2401-E2412

  2. Confirmed disability progression as a marker of permanent disability in multiple sclerosis

    European Journal of Neurology, Vol. 29, Núm. 8, pp. 2321-2334

  3. Consensus on early detection of disease progression in patients with multiple sclerosis

    Frontiers in Neurology, Vol. 13

  4. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

  5. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

    Neurology, Vol. 99, Núm. 17, pp. E1926-E1944

  6. Identification of the genetic mechanism that associates L3MBTL3 to multiple sclerosis

    Human Molecular Genetics, Vol. 31, Núm. 13, pp. 2155-2163

2021

  1. Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

    Multiple Sclerosis Journal, Vol. 27, Núm. 5, pp. 755-766

  2. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

    Neurology, Vol. 96, Núm. 5, pp. e783-e797

2020

  1. A new risk variant for multiple sclerosis at 11q23.3 locus is associated with expansion of CXCR5+ circulating regulatory T cells

    Journal of Clinical Medicine, Vol. 9, Núm. 3

  2. Delay from treatment start to full effect of immunotherapies for multiple sclerosis

    Brain, Vol. 143, Núm. 9, pp. 2742-2756

  3. Risk of secondary progressive multiple sclerosis: A longitudinal study

    Multiple Sclerosis Journal, Vol. 26, Núm. 1, pp. 79-90

  4. XII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2019 (I)

    Revista de neurologia, Vol. 70, Núm. 10, pp. 379-390

  5. XII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2019 (II)

    Revista de neurologia, Vol. 70, Núm. 11, pp. 417-429

2019

  1. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study

    European Journal of Neurology, Vol. 26, Núm. 2, pp. 363-370